Pluristem Therapeutics Inc (PSTI)

[FDApproved]

Official Title: A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation

Since It Is An Open Label Study. The Data Is Available For Pluristem And The FDA Quickly, As The Results Would Be Known Just A Couple Of Weeks After The 2nd Injection.


Experimental: PLX-R18
Dose Escalation- first three subjects will be enrolled in the low dose cohort, 12 subjects in the intermediate-dose cohort, and 15 subjects in the high dose cohort.

Yaky Said In A Recent Interview That They Intend To "Flood" The FDA With Efficacy Data From Multiple Sources.